N-(4-hydroxyphenyl)retinamide activation of transforming growth factor- β and induction of apoptosis in human breast cancer cells

Nutrition and Cancer

Volumn 34, Issue 2, 1999, Pages 121-132

  Herbert, Brittney Shea ^a,b   Sanders, Bob G ^a   Kline, Kimberly ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; CYTOKINE ANTIBODY; DNA; FENRETINIDE; RETINOIC ACID DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DNA SYNTHESIS; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NUCLEIC ACID PROBE; REPORTER GENE;

EID: 0032713840     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1207/S15327914NC3402_1     Document Type: Article

References (75)

1. Moon, RC, Mehta, RG, and Detrisac, CJ: Retinoids as chemopreventive agents for breast cancer. Cancer Detect Prev 16, 73-79, 1992.
2. Modiano, MR, Dalton, WS, Lippman, SM, Joffe, L, Booth, AR, et al.: Phase II study of fenretinide, N-(4-hydroxyphenyl)retinamide, in advanced breast cancer and melanoma. Invest New Drugs 8, 317-319, 1990.
3. Veronesi, U, De Palo, G, Costa, A, Formelli, F, Marubini, E, et al.: Chemoprevention of breast cancer with retinoids. JNCI 12, 93-97, 1992.
4. Kelloff, GJ, Crowell, JA, Boone, CW, Steele, VE, Lubet, RA, et al.: Clinical development plan: N-(4-hydroxyphenyl)retinamide. J Cell Biochem 20, 176-196, 1994.
5. Kelloff, GJ, Boone, CW, Crowell, JA, Steele, VE, Lubet, RA, et al.: New agents for cancer chemoprevention. J Cell Biochem 26, 1-28, 1996.
6. Formelli, F, Barua, AB, and Olson, JA: Bioactivities of N-(4-hydroxyphenyl)retinamide and retinoyl β-glucuronide. FASEB J 10, 1014-1024, 1996.
7. Pollard, M, and Luckert, PH: The inhibitory effect of 4-hydroxyphenyl retinamide (4-HPR) on metastasis of prostate adenocarcinoma-III cells in Lobund-Wistar rats. Cancer Lett 59, 159-163, 1991.
8. Bhatnagar, R, Abou-Issa, H, Curley, RW, Jr, Koolemans-Beynen, A, Moeschberger, ML, et al.: Growth suppression of human breast carcinoma cells in culture by N-(4-hydroxyphenyl)retinamide and its glucuronide and through synergism with glucarate. Biochem Pharmacol 41, 1471-1477, 1991.
9. Wang, TTY, and Phang, JM: Effect of N-(4-hydroxyphenyl)retinamide on apoptosis in human breast cancer cells. Cancer Lett 10, 65-71, 1996.
10. Sheikh, MS, Shao, Z, Li, XS, Ordonez, JV, Conley, BA, et al.: N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. Carcinogenesis 16, 2477-2486, 1995.
11. Fanjul, AN, Delia, D, Pierotti, MA, Rideout, D, Qiu, J, et al.: 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J Biol Chem 271, 22441-22446, 1996.
12. Kazmi, SMI, Plante, RK, Visconti, V, and Lau, CY: Comparison of N-(4-hydroxyphenyl)retinamide and all-trans-retinoic acid in the regulation of retinoid receptor-mediated gene expression in human breast cancer cell lines. Cancer Res 56, 1056-1062, 1996.
13. Chiesa, F, Tradati, N, Marazza, M, Rossi, N, Boracchi, P, et al.: Chemoprevention of local relapses and new localizations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Preliminary results. Eur J Cancer 28B, 97-102, 1992.
14. DePalo, G, Veronesi, U, Camerini, T, Formelli, F, Mascotti, G, et al.: Can fenretinide protect women against ovarian cancer? JNCI 87, 146-147, 1995.
15. Veronesi, U, De Palo, G, Costa, A, Formelli, F, and Decensi, A: Chemoprevention of Breast Cancer With Fenretinide. Lyon, France: Int Agency Res Cancer, 1996, pp 87-94. (IARC Sci Publ 136)
16. Greenwald, P: Cancer risk factors for selecting cohorts for large-scale chemoprevention trials. J Cell Biochem Suppl 25, 29-36, 1996.
17. Delia, D, Aiello, A, Lombardi, L, Pelicci, PG, Grignani, F, et al.: N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cells including those unresponsive to retinoic acid. Cancer Res 53, 6036-6041, 1993.
18. Roberson, KM, Penland, SN, Padilla, GM, Selvan, RS, Kim, CS, et al.: Fenretinide: induction of apoptosis and endogenous transforming growth factor β in PC-3 prostate cancer cells. Cell Growth Differ 8, 101-111, 1997.
19. Di Vinci, A, Geido, E, Infusini, E, and Giaretti, W: Neuroblastoma cell apoptosis induced by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. Int J Cancer 59, 422-426, 1994.
20. Marlotti, A, Marcoro, E, Bunone, G, Costa, A, Veronesi, U, et al.: N-(4-hydroxyphenyl)retinamide: a potent inducer of apoptosis in human neuroblastoma cells. JNCI 86, 1245-1247, 1994.
21. Dmitrovsky, E: N-(4-hydroxyphenyl)retinamide activation of a distinct pathway signaling apoptosis. JNCI 89, 1179-1181, 1997.
22. Moses, HL, Yang, EY, and Pietenpol, JA: TGF-β stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 63, 245-247, 1990.
23. Roberts, AB, and Sporn, MB: The transforming growth factor-βs. In Peptides, Growth Factors and Their Receptors: Handbook of Experimental Pharmacology, MB Sporn and AB Roberts (eds). Berlin: Springer-Verlag, 1990, pp 419-472.
24. Massague, J: The transforming growth factor-β family. Annu Rev Cell Biol 6, 597-641, 1990.
25. Lin, HY, and Lodish, HF: Receptors for the TGF-β superfamily: multiple polypeptides and serine/threonine kinases. Trends Cell Biol 3, 14-19, 1993.
26. Roberts, AB, and Sporn, MB: Transforming growth factor-β. In Human Cytokines, BB Aggarwal and JU Gutterman (eds). Boston, MA: Blackwell, 1992, pp 399-417.
27. Munger, JS, Harpel, JG, Gleizes, P, Mazzieri, R, Nunes, I, et al.: Latent transforming growth factor-β: structural features and mechanisms of activation. Kidney Int 51, 1376-1382, 1997.
28. Nunes, I, Kojima, S, and Rifkin, DB: Effects of endogenously activated transforming growth factor-β on growth and differentiation of retinoic acid-treated HL-60 cells. Cancer Res 56, 495-499, 1996.
29. Dennis, PA, and Rifkin, DB: Cellular activation of latent transforming growth factor β requires binding to the cation-independent mannose-6-phosphate/insulin-like growth factor type II receptor. Proc Natl Acad Sci USA 88, 580-584, 1991.
30. Wakefield, LM, Colletta, AA, McCune, BK, and Sporn, MB: Roles for transforming growth factor-β in the genesis, prevention, and treatment of breast cancer. In Genes, Oncogenes, and Hormones: Advances in Cellular and Molecular Biology of Breast Cancer, RB Dickson and ME Lippman (eds). Boston, MA: Kluwer, 1991, pp 79-136.
31. Wakefield, LM, Letterio, JJ, Geiser, AG, Flanders, KC, O'Shaughnessy, J, et al.: Transforming growth factor-βs in mammary tumorigenesis: promoters or antipromoters? Prog Clin Biol Res 391, 133-148, 1995.
32. Massague, J: Receptors for the TGF-β family. Cell 69, 1067-1070, 1992.
33. Massague, J: TGF-β signaling: receptors, transducers, and Mad proteins. Cell 85, 947-950, 1996.
34. Kline, K, Yu, W, and Sanders, BG: Vitamin E: mechanisms of action as tumor cell growth inhibitors. In Proceedings of the International Conference on Nutrition and Cancer, KN Prasad (ed). Amsterdam: IOS, 1997, pp 37-54.
35. 1 and its receptors during all-trans-retinoic acid (RA) treatment of RA-responsive human neuroblastoma cell lines. Cancer Res 55, 2380-2386, 1995.
36. 1 (TGF-β) in myeloid leukemia cell lines (abstr). Proc Am Assoc Cancer Res 34, 46, 1993.
37. 3 in MG-63 osteoblastic cells. Biochem Biophys Res Commun 204, 918-923, 1994.
38. 1 and its latent form binding protein in culture breast carcinoma cells. Cancer Res 55, 1540-1546, 1995.
39. Colletta, AA, Wakefield, LM, Howell, FV, Danielpour, D, Baum, M, et al.: The growth inhibition of human breast cancer cells by a novel synthetic progestin involves the induction of transforming growth factor β. J Clin Invest 87, 277-283, 1991.
40. 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 52, 4261-4264, 1992.
41. Colletta, AA, Wakefield, LM, Howell, FV, van Roozendaal, KEP, Danielpour, D, et al.: Anti-oestrogens induce the secretion of active transforming growth factor β from human fetal fibroblasts. Br J Cancer 62, 405-409, 1990.
42. Wakefield, LM, Kim, S-J, Click, A, Winokur, T, Colletta, A, et al.: Regulation of transforming growth factor-β subtypes by members of the steroid hormone superfamily. J Cell Sci Suppl 13, 139-148, 1990.
43. Mills, JJ, Chari, RS, Boyer, IJ, Could, MN, and Jirtle, R: Induction of apoptosis in liver tumors by the monoterpene perillyl alcohol. Cancer Res 55, 979-983, 1995.
44. Haag, JD, Lindstrom, W, and Gould, MN: Limonene-induced regression of mammary carcinomas. Cancer Res 52, 4021-4026, 1992.
45. Haag, JD, and Gould, MN: Mammary carcinoma regression induced by perillyl alcohol, a hydroxylated analog of limonene. Cancer Chemother Pharmacol 34, 477-483, 1994.
46. Price, JE, Polyzos, A, Zhang, RD, and Daniels, LM: Tumorigenicity and metastasis of human breast cancer carcinoma cell lines in nude mice. Cancer Res 50, 717-721, 1990.
47. Abe, M, Harpel, JG, Metz, CN, Nunes, I, Loskutoff, DJ, et al.: An assay for transforming growth factor-β using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem 216, 267-284, 1994.
48. Yu, W, Heim, K, Qian, M, Simmons-Menchaca, M, Sanders, BG, et al.: Evidence for role of transforming growth factor-β in RRR-α-to-copheryl succinate-induced apoptosis of human MDA-MB-435 breast cancer cells. Nutr Cancer 27, 267-278, 1997.
49. Laemmli, UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685, 1970.
50. Kalkhoven, E, Roelen, B, de Winter, JP, Mummery, CL, van den Eijnden-van Raaij, AJ, et al.: Resistance to transforming growth factor β and activin due to reduced receptor expression in human breast tumor cell lines. Cell Growth Differ 6, 1151-1161, 1995.
51. White, E: Life, death, and the pursuit of apoptosis. Genes Dev 10, 1-15, 1996.
52. Kerr, JFR Wyllie, AH, and Currie, AR: Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer 26, 1790-1794, 1972.
53. Martin, SJ, Green, DR, and Cotter, TG: Dicing with death: dissecting the components of the apoptosis machinery. Trends Biochem Sci 19, 26-30, 1994.
54. Markowitz, SD, and Roberts, AB: Tumor suppressor activity of the TGF-β pathway in human cancers. Cytokine Growth Factor Rev 7, 93-102, 1996.
55. Hosobuchi, M, and Stampfer, MR: Effects of transforming growth factor β on growth of human mammary epithelial cells in culture. In Vitro Cell Dev Biol 25, 705-713, 1989.
56. Arteaga, CL, Coffey, RJ, Dugger, TC, McCutchen, M, Moses, HL, et al.: Growth stimulation of human breast cancer cells with anti-transforming growth factor β antibodies: evidence for negative autocrine growth regulation by transforming growth factor β. Cell Growth Differ 1, 367-374, 1990.
57. Dickens, TA, and Colletta, AA: The pharmacological manipulation of members of the transforming growth factor-β family in the chemoprevention of breast cancer. Bioessays 15, 71-74, 1993.
58. Robinson, SD, Silberstein, GB, Roberts, AB, Flanders, KC, and Daniel, CW: Regulated expression and growth inhibitory effects of transforming growth factor-β isoforms in mouse mammary gland development. Development 113, 867-878, 1991.
59. 1-induced growth inhibition of mouse mammary ductal growth: developmental specificity and characterization. Dev Biol 135, 20-30, 1989.
60. Koli, KM, and Arteaga, CL: Predominant cytosolic localization of type II transforming growth factor-β receptors in human breast carcinoma cells. Cancer Res 57, 970-977, 1997.
61. Charpentier, A, Groves, S, Simmons-Menchaca, M, Turley, JM, Zhao, B, et al.: RRR-α-tocopheryl succinate inhibits proliferation and enhances secretion of transforming growth factor-β (TGF-β) by human breast cancer cells. Nutr Cancer 19, 225-239, 1993.
62. 3 and TGF-βR-II expression by human MDA-MB-435 breast cancer cells. Nutr Cancer 26, 237-250, 1996.
63. Kline, K, Yu, W, Zhao, B, Israel, K, Charpentier, A, et al.: Vitamin E succinate: mechanisms of action as tumor cell growth inhibitor. In Nutrients in Cancer Prevention and Treatment, KN Prasad, L Santamaria, and RM Willams (eds). Totowa, NJ: Humana, 1995, pp 189-205.
64. Gould, MN: Prevention and therapy of mammary cancer by monoterpenes. J Cell Biochem 22, 139-144, 1995.
65. Ariazi, EA, and Gould, MN: Identifying differential gene expression in monoterpene-treated mammary carcinoma using subtractive display. J Biol Chem 271, 29286-29294, 1996.
66. Moore, DD: Diversity and unity in the nuclear hormone receptors: a terpenoid receptor superfamily. New Biol 2, 100-105, 1990.
67. Sanchez, A, Alvarez, AM, Benito, M, and Fabregat, I: Apoptosis induced by transforming growth factor-β in fetal hepatocyte primary cultures: involvement of reactive oxygen intermediates. J Biol Chem 271, 7416-7422, 1996.
68. 1-induced apoptosis of myeloid leukemia cells. Mol Cell Biol 14, 2352-2360, 1994.
69. Yu, W, Sanders, BG, and Kline, K: RRR-α-tocopheryl succinate inhibits EL-4 thymic lymphoma cell growth by inducing apoptosis and DNA synthesis arrest. Nutr Cancer 27, 92-101, 1997.
70. Jing, Y, Zhang, J, Waxman, S, and Mira-y-Lopez, R: Upregulation of cytokeratins 8 and 18 in human breast cancer T47D cells is retinoid-specific and retinoic acid receptor-dependent. Differentiation 60,109-117, 1996.
71. Delia, D, Aillo, A, Formelli, F, Fontanella, E, Costa, A, et al.: Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl)retinamide and effect of deregulated bcl-2. Blood 85, 359-367, 1995.
72. Delia, D, Aiello, A, Meroni, L, Nicolini, M, Reed, JC, et al.: Role of antioxidants and intracellular free radicals in retinamide-induced cell death. Carcinogenesis 18, 943-948, 1997.
73. Oridate, N, Lotan, D, Xu, X-C, Hong, W, and Lotan, R: Differential induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl)retinamide in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res 2, 855-863, 1996.
74. 1-induced apoptosis in human ovarian carcinoma cells: protection by the antioxidant N-acetylcysteine and bcl-2. Cell Growth Differ 7, 1095-1104, 1996.
75. Sanchez, A, Alvarez, AM, Benito, M, and Fabregat, I: Cyctoheximide prevents apoptosis, reactive oxygen species production, and glutathione depletion induced by transforming growth factor β in fetal rat hepatocytes in primary culture. Hepatology 26, 935-943, 1997.